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Abstract Over the last 20 years, several studies have
investigated the ability of glucosamine sulfate to improve
the symptoms (pain and function) and to delay the struc-
tural progression of osteoarthritis. There is now a large,
convergent body of evidence that glucosamine sulfate,
given at a daily oral dose of 1,500 mg, is able to signifi-
cantly reduce the symptoms of osteoarthritis in the lower
limbs. This dose of glucosamine sulfate has also been
shown, in two independent studies, to prevent the joint
space narrowing observed at the femorotibial compartment
in patients with mild-to-moderate knee osteoarthritis. This
effect also translated into a 50 % reduction in the incidence
of osteoarthritis-related surgery of the lower limbs during a
5-year period following the withdrawal of the treatment.
Some discrepancies have been described between the
results of studies performed with a patent-protected for-
mulation of glucosamine sulfate distributed as a drug and
those having used glucosamine preparations purchased
from global suppliers, packaged, and sold over-the-counter
as nutritional supplements.
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Preclinical research
Glucosamine is an aminosaccharide, acting as a preferred
substrate for the biosynthesis of glycosaminoglycan chains
and, subsequently, for the production of aggrecan and other
proteoglycans of cartilage [1]. Because of the essential role
aggrecans play in giving the cartilage its hydrophilicity,
compounds enhancing synthesis of aggrecans may be
beneficial in cases of OA, a disorder characterized by an
increase in matrix structural protein turnover, with catab-
olism being predominant over synthesis [2].
In vitro, glucosamine sulfate (GS) has been demon-
strated to reduce prostaglandin E2 (PGE2) production and
interfere with nuclear factor kappa B (NF_B) DNA binding
in chondrocytes and synovial cells [3, 4].
Glucosamine inhibits gene expression of OA cartilage in
vitro [5]. Long-term oral administration of glucosamine
sulfate reduces the destruction of cartilage and upregula-
tion of MMP-3 mRNA in a model of spontaneous osteo-
arthritis in Harley guinea pigs [6]. Glucosamine can
prevent cytokine-induced demethylation of a specific CpG
site in the IL1b promoter and this is associated with
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decreased expression of IL1b [7]. It was suggested that
since glucosamine inhibits both anabolic and catabolic
genes, the therapeutic effects of glucosamine might be due
to anticatabolic activities, rather than due to anabolic
activities. GS is a stronger inhibitor of gene expression than
glucosamine hydrochloride [8, 9].
Symptomatic effects in osteoarthritis
Efficacy and safety of GS were tested in several random-
ized, controlled clinical trials that included patients with
OA, predominantly of the knee or spine. In OA of the knee,
intramuscular GS (400 mg twice/week for 6 weeks) was
compared to a placebo (n = 155). At the end of the
treatment and 2 weeks after drug discontinuation, a sig-
nificant difference in the decrease in the Lequesne’s index
(an index assessing pain and function and initially devel-
oped to identify patients in the need for surgical joint
replacement) was observed for the GS group compared to
the placebo. A positive rate (responders were those patients
with at least a three-point reduction in the Lequesne’s
index) was significantly higher in the GS group when
considering evaluable patients (55 vs. 33 %) or by inten-
tion-to-treat analysis (51 vs. 30 %) [10].
To optimize the long-term compliance of osteoarthritic
patients with OA, glucosamine was administered predom-
inantly orally in subsequent clinical trials. In 252 outpa-
tients with OA of the knee [stage I, III], those treated with
1,500 mg/day GS for 4 weeks had a significantly higher
decrease in the Lequesne’s index than those receiving a
placebo. The response rates were within the same range as
those observed with the intramuscular formulation (55 vs.
38 % evaluable patients; 52 vs. 37 % patients in an
intention-to-treat analysis) [11]. These results were con-
firmed by a 16-week, randomized, double-blind placebo-
controlled crossover trial of a combination of glucosamine
HCl (1,500 mg/day), chondroitin sulfate (1,200 mg/day),
and manganese ascorbate (228 mg/day), performed in 34
males from the US Navy diving and special warfare
community with chronic pain and radiographic degenera-
tive joint diseases of the knee or low back. While the study
did not demonstrate, or exclude, a benefit for the spine,
knee OA symptoms were relieved, as evidenced by the
changes observed in a summary disease score, incorporat-
ing results of pain and functional questionnaire, physical
examination score, and running time [12].
In a 3-year trial including 319 patients randomized to
1,500 mg/day of GS or a placebo, preliminary results
suggested that GS significantly improved the long-term
symptomatic evolution of knee OA assessed by Lequesne’s
Algo-Functional index [13]. However, it was observed that
glucosamine hydrochloride does not induce symptomatic
relief in knee OA to the same extent that GS does. In an
8-week double-blind, placebo-controlled study, followed
by 8 weeks off-treatment observation, glucosamine
hydrochloride yielded only beneficial results in response to
a daily diary pain questionnaire with no effects on the
primary endpoint (WOMAC questionnaire) [14]. This
questions the importance of sulfate and its contribution to
the overall effects of glucosamine.
GS (1,500 mg/day) was also compared to placebo in 162
outpatients with spinal OA (68 with cervical, 57 with
lumbar, and 37 with thoracic localizations) and induced a
significant improvement of pain and function parameters
(visual analog scale) at all localizations. The improvement
with glucosamine lasted up to 4 weeks after drug discon-
tinuation [15].
The symptomatic action of GS was also compared to
that of nonsteroidal anti-inflammatory drugs. GS
(1,500 mg orally) and ibuprofen (1,200 mg) had the same
success rate (48 % for GS vs. 52 % for ibuprofen) after
4 weeks in 200 hospitalized patients with OA of the knee.
The effect of ibuprofen tended to occur sooner than that of
GS (48 % ibuprofen vs. 28 % GS after the first week of
treatment). However, significantly fewer patients reported
adverse effects (mainly of gastrointestinal origin) with GS
(6 %) than with ibuprofen (35 %), and the number of
adverse event-related dropouts differed between the two
groups (7 % ibuprofen vs. 1 % GS) [16]. These results
were perfectly duplicated in another study that included 68
Chinese patients with a nonsignificant difference between
ibuprofen and GS (in favor of GS) in the reduction in the
symptoms of OA, but GS was better tolerated (6 % of
patients with adverse reactions and 0 % of drug-related
dropouts) than ibuprofen (16 % of adverse reactions and
0 % of drug-related dropouts) [17]. A total of 319
patients with symptomatic OA of the knee received GS
(1,500 mg/day), piroxicam (20 mg/day), both drugs, or a
placebo for 12 weeks followed by 8 weeks without treat-
ment. In the GS group, the Lequesne’s index decreased by
4.8 points during treatment, for a decrease of 2.9 and 0.7
points, in the piroxicam and placebo groups, respectively
(p \ 0.001). The association did not differ from GS alone.
GS did not differ in safety (14.8 % incidence of adverse
events during treatment) from placebo (23.7 %) but was
significantly better tolerated than piroxicam (40.9 %) or the
association (35 %). The improvement in GS-treated
patients persisted during the 8-week follow-up period,
whereas the improvement with piroxicam did not [18].
In 45 adult subjects diagnosed with temporomandibular
joint (TMJ) OA, GS (1,500 mg/day) and ibuprofen
(1,200 mg/day), given for 90 days, both induced significant
improvement in TMJ pain with function and pain-free and
voluntary maximum mouth opening. Between-groups
comparison reveled that patients taking GS have a
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significant greater decrease in TMJ pain with function and
used less acetaminophen (chosen as rescue medication)
during the 30-day period following the treatment [19].
Few investigations have tested alternative routes of
administration for GS. No head-to-head comparison
between the oral and topical routes is currently available.
However, a topical application of a preparation containing
glucosamine sulfate, chondroitin sulfate, and shark carti-
lage reduced, within 4 weeks, pain related to knee OA to a
significantly greater extend than a placebo cream [20].
Studies with less stringent methodology did not, how-
ever, systematically replicate these positive results. In a
study of pragmatic design, including 80 patients with a
wide range of pain severity from knee OA, the adminis-
tration of GS (1,500 mg/day for 6 months) did not provide
significant pain relief compared to the administration of
calcium carbonate (CC). It should be emphasized, how-
ever, that the GS preparation used in this trial was an over-
the-counter (OTC) formulation containing a mixture of GS,
vitamin C, and CC [21]. Similarly, when using another
OTC preparation of GS, Rindone et al. [22] were unable to
detect an analgesic effect of 1,500 mg of GS daily over
2 months, compared to placebo, in 98 patients with OA of
the knee. Both studies were performed with GS prepara-
tions purchased from global suppliers and packaged and
sold OTC as nutritional supplements. They are not regu-
lated as drugs and might have important variations in
content [23, 24]. Noteworthy is that both above-referenced
trials [21, 22] were conducted without performing any
quality control assays for GS. In a prototypical double-
blind, randomized, placebo trial of GS (1,500 mg/day)
among subjects recruited and followed entirely over the
Internet, no differences between treatment and control
groups were observed over 12 weeks concerning pain,
stiffness, or function on total WOMAC scores. In this trial,
the initial GS (OTC) provider declined to supply placebo
capsules during the course of the study and the patients
were subsequently treated with a glucosamine HCl for-
mulation, manufactured to pharmaceutical grade purity
[25].
A National Institutes of Health sponsored study labelled
the glucosamine/chondroitin arthritis intervention trial
(GAIT), examined placebo versus glucosamine hydro-
chloride (500 mg three times daily) versus chondroitin
sulfate (400 mg three times daily) versus the combina-
tion of glucosamine and chondroitin versus celecoxib
(200 mg/day) in a parallel, and blinded 6-month multi-
centre study of response in knee OA [26]. The primary
efficacy variable was a 20 % improvement in knee pain
from baseline to 24 weeks. Overall, glucosamine hydro-
chloride and chondroitin sulfate were not significantly
better than placebo in reducing knee pain by 20 %. How-
ever, for patients with moderate-to-severe pain at baseline,
the rate of response (OMERACT–OARSI criteria) was
significantly higher with combined therapy than with pla-
cebo (79.2 vs. 54.3 %, p = 0.002).
The Glucosamine Unum In Die [once-a-day] Efficacy
(GUIDE) trial, a 6-month double-blind, multicentre trial in
Spain and Portugal examining placebo versus GS
(1,500 mg once daily) versus acetaminophen (3,000 mg/
day), has also recently been presented [8, 27]. The primary
efficacy variable was a change in the Lequesne Algo-
Functional index. Although there was a numeric difference
in improvement in the Lequesne Algo-Functional index
between acetaminophen and placebo, only the improve-
ment in the Lequesne Algo-Functional index for GS versus
placebo was significant (p = 0.032). Secondary analyses,
including the OARSI responder indices, were significant
for glucosamine (p = 0.004).
There are several potential confounders that may have
relevance when trying to interpret the seemingly contra-
dictory results of the clinical trials, such as the GAIT and
GUIDE.
1. In North America, glucosamine hydrochloride or
sulfate and chondroitin sulfate are considered nutra-
ceuticals, whereas in most European countries, these
are marketed as pharmaceuticals. Therefore, produc-
tion and marketing of glucosamine are more closely
monitored in Europe. In North America, varying
quantities of glucosamine have been noted in a survey
of several nutraceuticals [28].
2. Most of the negative clinical trials were performed
with glucosamine hydrochloride 500 mg three times
daily, whereas most of the positive trials were
performed with the GS powder for oral solution at
the dose of 1,500 mg once daily. This obviously raises
the question, so far unanswered, of the importance of
sulfate and of its contribution to the overall effects of
glucosamine. Although the sulfate is readily hydro-
lyzed from the glucosamine in the gastrointestinal
tract, there are suggestions that sulfate is in itself
clinically relevant [29, 30].
3. Interestingly, the most clinically relevant results in
GAIT were seen when sodium chondroitin sulfate was
taken with glucosamine hydrochloride; whether this
may be explained by an increase in the bioavailabi-
lity of sulfates together with glucosamine requires
further study. It is of note that several of the
glucosamine preparations contain other salts that could
potentially influence uptake and utilization of gluco-
samine [31].
4. The placebo response for many clinical trials with oral
agents in treatment for knee OA has traditionally been
around 30 % [32] and these usual figures were
replicated in the GUIDE study. The high placebo
Rheumatol Int (2012) 32:2959–2967 2961
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response in the GAIT (60.1 %) is of unknown
significance.
Although there has been a public comment that the
differences in the trials are due to corporate vs noncorpo-
rate sponsorship, there have been no data produced to
support such allegation. Indeed, one could argue that the
differences in results were more from the differences in
product, study design, and study populations [33].
The symptomatic efficacy of glucosamine in OA has
been analyzed through high-quality quantitative systematic
reviews [34–37].
The Cochrane Database of Systematic Reviews on glu-
cosamine included 20 studies with 2,570 patients. Pooled
results from studies using a noncrystalline preparation or
adequate allocation concealment failed to show benefit in
pain and WOMAC function, while those studies evaluating
the crystalline preparation show that glucosamine was
superior to placebo in the treatment of pain and functional
impairment resulting from symptomatic OA. Glucosamine
was found to be superior for pain (SMD -1.31, 95 % CI
-1.99, -0.64) and function using the Lequesne index
(SMD -0.51, 95 % CI -0.96, -0.05). WOMAC outcomes
of pain, stiffness, and function did not show a superiority of
glucosamine over placebo for both crystalline and non-
crystalline preparations of glucosamine. Glucosamine was
considered as safe as placebo, in terms of the number of
subjects reporting adverse reactions (RR = 0.97, 95 % CI
0.88, 1.08) [38].
Recommendations using on the GRADE (Grading of
Recommendations Assessment, Development and Evalua-
tion) system, a system based on a sequential assessment of
the quality of evidence, followed by assessment of the
balance between benefits versus downsides and subsequent
judgment about the strength of recommendations, con-
cluded that glucosamine sulfate demonstrated pain reduc-
tion and physical function improvement with very low
toxicity and with moderate- to high-quality evidence [39].
Structural effects in osteoarthritis
To test the long-term effects of GS on the progression of
OA joints structural changes and symptoms, two parallel
studies including, respectively, 212 and 202 patients with
knee OA were designed. Patients were randomly assigned
in a double-blind fashion to a continuous treatment with
GS (1,500 mg once/day) or placebo for 3 years. Weight-
bearing, anteroposterior radiographs of each knee were
taken at enrollment and after 1 and 3 years, standardizing
patients’ positioning and radiographic procedures. Total
mean joint space width of the medial compartment of the
tibiofemoral joint was assessed by digital image analysis
by a validated computerized algorithm, with the narrowest
joint space at enrollment being taken for the primary
evaluation (signal joint). Symptoms were scored at each
4-month visit by a total WOMAC index or Lequesne’s
Algo-Functional index.
In the first trial, the 106 patients on placebo had pro-
gressive joint space narrowing, with a mean joint space loss
after 3 years of -0.31 mm (95 % = -0.48 to -0.13).
There was no significant joint space loss in the 106 patients
on glucosamine sulfate: -0.06 mm (-0.22 to 0.09). Sim-
ilar results were reported with minimum joint space nar-
rowing. As assessed by WOMAC scores, symptoms
worsened slightly in patients on placebo compared with the
improvement observed after treatment with glucosamine
sulfate. There were no differences in safety or reasons for
early withdrawal between the treatment and placebo groups
[40].
In the second trial, progressive joint space narrowing
with placebo use was -0.19 mm (95 % confidential
interval, -0.29 to -0.09 mm) after 3 years. Conversely,
there was no average change with glucosamine sulfate use
(0.04 mm; 95 % confidence interval, -0.06 to 0.14 mm),
with a significant difference between groups (p = 0.001).
Fewer patients treated with glucosamine sulfate experi-
enced predefined severe narrowing ([0.5 mm): 5 vs. 14 %
(p = 0.05). Symptoms improved modestly with placebo
use but as much as 20–25 % with glucosamine sulfate use,
with significant final differences on the Lequesne index and
the WOMAC total index and pain, function, and stiffness
subscales. Safety was good and without differences
between groups [41].
Additional post hoc analyses were performed in order to
identify patients who would be particularly responsive to
GS as a symptom or structure-modifying drug.
At baseline, in the overall population, mean joint space
width (JSW) and narrowest joint space (NJS) point were
not significantly correlated with the scores recorded for
the WOMAC global index or its pain, stiffness, or function
subscales. A statistically significant correlation was
observed between the joint space narrowing over 3 years
and stiffness or function subscale of the WOMAC during
the same period. The 3-year changes in the global
WOMAC index in patients within the lowest and highest
quartiles of mean joint space width at baseline showed, in
both cases, a statistically (p \ 0.05) significant favorable
difference between patients treated with glucosamine sul-
fate and those having received a placebo [42].
In the placebo group, baseline joint space width was
significantly and negatively correlated with the joint space
narrowing observed after 3 years (r = 0.34, p = 0.003). In
the lowest quartile of baseline mean joint space width
(\4.5 mm), the joint space width increased after 3 years by
a mean of 3.8 % (SD: 23.8) in the placebo group and 6.2 %
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(SD: 17.5) in the glucosamine sulfate group. The difference
between the two groups of patients’ with severe OA at
baseline was not statistically significant (p = 0.70). In the
highest quartile of baseline mean joint space width
([6.2 mm), a joint space narrowing of 14.9 % (SD: 17.9)
occurred in the placebo group after 3 years, while patients
from the glucosamine sulfate group, only experienced a
narrowing of 6.0 % (SD: 15.1). Patients with the most
severe OA at baseline had a relative risk (RR) of 0.42
(0.17–1.01) to experience a 0.5 mm joint space narrowing
over 3 years, compared to those with the less affected joint.
In patients with mild OA, (i.e., in the highest quartile of
baseline mean joint space width), glucosamine sulfate use
was associated with a trend (p = 0.10) toward a significant
reduction in joint space narrowing [43].
These results were further supported by the demonstra-
tion that patients with the highest cartilage turnover at
baseline, presented a decrease in collagen type II degra-
dation (CTXII) after 12 months of GS therapy, and that
these changes in CTX-II were correlated with the changes
in average joint space width observed after 36 months [44].
These results suggest that patients with a less severe
radiographic knee OA will be particularly responsive to GS
as a structure-modifying drug. However, GS provides long-
term relief of symptoms independently of baseline joint
space width in patients with mild to moderate osteoarthritis
of the knee.
These studies were, however, challenged for the poten-
tial systematic error that might have been introduced by the
major effect observed—the significant improvement of
symptoms in the GS-treated patients compared with pla-
cebo-treated patients. It has been hypothesized that the
concomitant reduction in pain seen in the glucosamine
sulfate arm, relative to placebo, altered the positioning of
the knee (in particular favoring a better knee full exten-
sion), resulting in a change in joint space width that might
have confounded the estimate of joint space narrowing and
exaggerated the difference between treatment groups [45].
This hypothesis, however, was demonstrated to be wrong
when it was shown that patients from the placebo group,
with a major clinical improvement, observed over 3 years,
did actually present with a joint space narrowing, while
patients with a similar significant symptomatic response, in
the GS group, did not experience this structural progres-
sion. Patients completing the 3-year treatment course were
selected based on a WOMAC pain decrease at least equal
to the mean improvement in the glucosamine sulfate arms
in either of the original studies, irrespective of treatment
with glucosamine sulfate or placebo (drug responders or
placebo responders). In a second approach, 3-year compl-
eters were selected if their baseline standing knee pain was
‘‘severe’’ or ‘‘extreme’’ and improved by any degree at the
end of the trials. In both cases, changes in minimum joint
space width were compared between treatment groups. The
placebo subsets in both studies underwent an evident mean
(SD) joint space narrowing, which was not observed with
glucosamine sulfate. Similar results were found in the
smaller subsets with greater than or equally severe baseline
standing knee pain that improved after 3 years, with a joint
space narrowing with placebo not observed with glucosa-
mine sulfate [46].
Although joint space narrowing, as judged on a stan-
dardized radiograph, is considered by regulatory agencies
as an appropriate primary endpoint for the evaluation of
drugs, whether the progression of OA is slowed down
through the use of GS has not been unequivocally estab-
lished [2].
Knee OA patients participating in two above-referenced
randomized, placebo-controlled, double-blind, 3-year trials
of glucosamine sulfate and receiving treatment for at least
12 months were systematically contacted to participate in a
long-term follow-up retrospective assessment of the inci-
dence of total knee replacement.
Out of 340 patients with at least 12 months of treatment,
275 (i.e., 81 %) could be retrieved and interviewed 131
formerly on placebo and 144 on glucosamine sulfate. There
were no differences in baseline disease characteristics
between groups or with the patients lost to follow-up. The
mean duration of follow-up was approximately 5 years
after trial termination and treatment discontinuation, mak-
ing up a total of 2,178 patient-years of observation
(including treatment and follow-up).
Total knee replacement had occurred in over twice as
many patients from the placebo group, 19 out of 131
(14.5 %), than in those formerly receiving glucosamine
sulfate, 9 out of 144 (6.3 %) (p = 0.024, chi-square test),
with a relative risk that was therefore 0.43 (95 % CI:
0.20–0.92), i.e., a 57 % decrease compared with placebo.
The Kaplan–Meier/logrank test survival analysis confirmed
a significantly decreased (p = 0.026) cumulative incidence
of total knee replacements in patients who had received
glucosamine sulfate [47].
A 24-month, double-blind, placebo-controlled study,
conducted at 9 sites in the United States as part of the
glucosamine/chondroitin arthritis intervention trial (GAIT),
enrolled 572 patients with knee OA who satisfied radio-
graphic criteria [Kellgren/Lawrence (K/L) grade 2 or grade
3 changes and joint space width (JSW) of at least 2 mm at
baseline]. Patients with primarily lateral compartment
narrowing at any time point were excluded. Patients who
had been randomized to 1 of the 5 groups in the GAIT
continued to receive glucosamine HCl 500 mg 3 times
daily, CS 400 mg 3 times daily, the combination of glu-
cosamine and CS, celecoxib 200 mg daily, or placebo
over 24 months. The minimum medial tibiofemoral JSW
was measured at baseline, 12 months, and 24 months.
Rheumatol Int (2012) 32:2959–2967 2963
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The primary outcome measure was the mean change in
JSW from baseline.
The mean JSW loss at 2 years in knees with OA in the
placebo group, adjusted for design and clinical factors, was
0.166 mm. No statistically significant difference in mean
JSW loss was observed in any treatment group compared
with the placebo group. Treatment effects on K/L grade 2
knees, but not on K/L grade 3 knees, showed a trend
toward improvement relative to the placebo group. The
power of the study was diminished by the limited sample
size, variance in JSW measurement, and a smaller than
expected loss in JSW [48]. This study confirmed the dif-
ferences in efficacy between the various glucosamine
preparations [49], or doses [50].
In a recent meta-analysis, the authors surveyed ran-
domized, controlled studies that examined the effects of
long-term daily glucosamine sulfate and chondroitin sul-
fate on joint space narrowing (JSN) in knee OA patients
using the Medline and the Cochrane Controlled Trials
Register, and by performing manual searches. Meta-anal-
ysis was performed using a fixed effect model because no
between-study heterogeneity was evident. Six studies
involving 1,502 cases were included in this meta-analysis,
which consisted of two studies on glucosamine sulfate.
Glucosamine sulfate did not show a significant effect ver-
sus controls on minimum JSN over the first year of treat-
ment (SMD 0.078, 95 % CI -0.116 to -0.273,
p = 0.429). However, after 3 years of treatment, glucosa-
mine sulfate revealed a small to moderate protective effect
on minimum JSN (SMD 0.432, 95 % CI 0.235–0.628,
p \ 0.001). This meta-analysis of available data shows that
glucosamine sulfate may delay radiological progression of
OA of the knee after daily administration for over 2 or
3 years [51].
Tolerance
The safety profile of GS was evaluated in a systematic
review of 12 randomized, controlled trials and was deemed
excellent, with 7 of 1,486 patients randomized to GS who
were withdrawn for GS-related toxicity and only 48 having
reported any GS-related adverse reactions [37].
Furthermore, an open study carried out by 252 physi-
cians throughout Portugal evaluated the tolerability of GS
in 1,208 patients. Patients were given, 500 mg GS orally, 3
times a day, for a mean period of 50.3 days (range:
13–99 days). Most patients (88 %) reported no side effects.
In the remaining 12 % of the study population, the reported
adverse effects were generally mild and predominantly
affected the gastrointestinal tract (e.g., epigastric pain,
heartburn, and diarrhea). All the reported complaints were
reversible with discontinuation of GS [52]. While some
questions were raised regarding the role of glucosamine in
glucose metabolism [53] and the possibility of increased
insulin resistance, a detailed review of scientific studies
performed with GS ruled out this possibility and
re-emphasized the safety of short- and long-term use of GS
[54].
While, in Europe, GS is regarded as a medication and is
thus subject to the usual quality controls, this is not so in
Canada and the United States. In Canada, GS is widely
available as a nutritional supplement and is not subject to
even rudimentary checks on purity. Glucosamine sulfate is
very hygroscopic and unstable. Hence, during manufac-
turing, varying amounts of potassium or sodium chloride
are added to improve stability. Because of concerns that the
labelling description may not always be valid [14], com-
mercially available capsules or tablets of GS were analyzed
in a coughed, blind manner, with a high-performance liquid
chromatography system. The amount of free base varied
from 41 to 108 % of the mg content stated on the label; the
amount of glucosamine varied from 59 to 138 % even
when expressed as sulfate [28]. Therefore, the results
obtained with one single preparation of GS, registered as a
drug in Europe, cannot be extrapolated to the vast majority
of OTC preparations sold without the appropriate quality
controls. In conclusion, however, there is a high degree of
consistency in the literature to consider that when a quality
product free of impurities is used, GS has an excellent
profile of safety [36, 55, 56] including no induction of
glucose intolerance in healthy adults [40, 57].
Health economics
A study was designed to explore the cost-effectiveness of
GS compared with paracetamol and placebo (PBO) in the
treatment for knee osteoarthritis, and a 6-month time
horizon and a health care perspective were used. The cost
and effectiveness data were derived from Western Ontario
and McMaster Universities Osteoarthritis Index data of the
Glucosamine Unum In Die (once-a-day) [58] Efficacy trial
study by Herrero-Beaumont et al. Clinical effectiveness
was converted into utility scores to allow for the compu-
tation of cost per quality-adjusted life year (QALY). For
the three treatment arms, incremental cost-effectiveness
ratio was calculated and statistical uncertainty was
explored using a bootstrap simulation. In terms of mean
utility score at baseline, 3 and 6 months, no statistically
significant difference was observed between the three
groups. When considering the mean utility score changes
from baseline to 3 and 6 months, no difference was
observed in the first case but there was a statistically sig-
nificant difference from baseline to 6 months with a
p value of 0.047. When comparing GS with paracetamol,
2964 Rheumatol Int (2012) 32:2959–2967
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the mean baseline incremental cost-effectiveness ratio
(ICER) was dominant and the mean ICER after boot-
strapping was -1,376 €/QALY indicating dominance (with
79 % probability). When comparing GS with PBO, the
mean baseline and after bootstrapping ICER were 3,617.47
and 4,285 €/QALY, respectively. The authors concluded
that GS is a highly cost-effective therapy alternative
compared with paracetamol and PBO to treat patients
diagnosed with primary knee OA.
Conclusions
GS has shown positive effects on symptomatic and struc-
tural outcomes of knee OA. These results should not be
extrapolated to other glucosamine salts [hydrochloride or
preparations over-the-counter or food supplements] in
which no warranty exists about content, pharmacokinetics,
and pharmacodynamics of the tablets.
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